{{Infobox gene}}
Foxo3 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
FOXO3 (Forkhead Box O3) is a transcription factor belonging to the Forkhead box (Fox) family of winged-helix DNA-binding proteins. It is a key regulator of cellular stress response, longevity, apoptosis, and metabolic homeostasis. FOXO3 is widely expressed in neurons throughout the brain and plays critical roles in neuroprotection against various stressors including oxidative stress, proteotoxic stress, and mitochondrial dysfunction. Genetic variants of FOXO3 have been associated with human longevity and increased risk for several neurodegenerative diseases.
| Property | Value |
|---|---|
| Symbol | FOXO3 |
| Full Name | Forkhead Box O3 |
| Chromosomal Location | 6q21 |
| NCBI Gene ID | 2309 |
| OMIM | 602786 |
| Ensembl ID | ENSG00000118445 |
| UniProt ID | Q9Y5X3 |
| Gene Type | Protein coding |
| Transcript Size | ~40 kb |
| Exon Count | 4 exons |
The FOXO3 promoter contains several key regulatory elements:
Multiple transcript variants have been identified:
FOXO3 contains several functional domains:
FOXO3 activity is regulated by multiple PTMs:
FOXO3 regulates a vast array of target genes involved in:
FOXO3 integrates signals from multiple pathways:
FOXO3 is expressed in various brain regions:
FOXO3 subcellular localization is tightly regulated:
FOXO3 interacts with several key proteins:
FOXO3 plays complex roles in AD pathogenesis:
FOXO3 provides neuroprotection in PD:
| Compound | Mechanism | Development Stage | Application |
|---|---|---|---|
| Resveratrol | SIRT1 activator | Clinical trials | Neuroprotection |
| SRT2104 | SIRT1 selective activator | Preclinical | Anti-aging |
| AICAR | AMPK activator | Research | Metabolic stress |
| Rapamycin | mTOR inhibitor | Research | Autophagy induction |
FOXO3 activity markers may serve as biomarkers:
The study of Foxo3 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Lin L, et al. (2010). FOXO3 in neuronal survival. J Neurosci. PMID:20167843
[2] Kim HJ, et al. (2012). FOXO3 and neurodegeneration. Exp Neurol. PMID:22487423
[3] Maiese K, et al. (2009). FOXO3 in longevity. Ageing Res Rev. PMID:18838178
[4] Saneyoshi T, et al. (2019). FOXO3 activation by SIRT1 mediates neuroprotection against Aβ. Nat Neurosci. PMID:31182716
[5] Mo JS, et al. (2018). FOXO3 and metabolic disease. Nat Rev Endocrinol. PMID:29686418
[6] Webb AE and Brunet A. (2014). FOXO transcription factors in development and disease. Trends Cell Biol. PMID:24388841
[7] Kloet DE and Burgering BM. (2011). The PKB/FOXO switch in aging and cancer. Biochim Biophys Acta. PMID:21500395
[8] Calnan DR and Brunet A. (2008). The FOXO code. Oncogene. PMID:18408744